Recent trial suggests Johnson & Johnson vaccine is effective against Delta variant

Source: MIGUEL MEDINA / Getty

A study by the South African Department of Health found that a single dose of the Johnson and Johnson vaccine could potentially prevent serious illness and death caused by the highly transmissible Delta and Beta variants.

The trial called Sisonke evaluated a group of nearly 500,000 healthcare workers who had received a single dose of the Johnson & Johnson vaccine. Studies have found that the vaccine has a 95 percent effectiveness rate against the Delta variant “and up to 71 percent against hospitalization” on New York Times Remarks. However, the results revealed that the vaccine was not able to fight the beta strain which is becoming increasingly difficult to fight infection, even among the vaccinated.

According to a report by CNBC, the variant contains “several important mutations in the spike protein of the virus – E484K, K417N and N501Y – which allow this variant to more easily infect people, while potentially making it more difficult to treat or prevent with vaccines. Covid. “

The WHO announced in July that although vaccines offer protection against “serious illness”, there is “possible reduced protection against symptomatic illnesses and infections.”

The good news is that the study suggests that people who have already received their single dose of the Johnson & Johnson vaccine will not be required to take a potential booster. The New York Times adds that 96 percent of vaccinated volunteers who were infected with the virus showed lower rates of serious illness and death in less than 0.05 percent of participants.

However, there are still questions about the safety of the Johnson and Johnson vaccine. In May, 28 women were diagnosed with a rare blood clotting disease after taking a single dose. Victims reportedly developed cerebral venous sinus thrombosis, or CVST, in association with a low blood platelet count within approximately two weeks of receiving the injection. CNBC reported.